Jabra Enhance Select 300 vs Otofonix Groove

The Jabra Enhance Select 300 is a premium OTC hearing aid priced at $1,695 that earns an A grade with a SoundScore of 4.1/5 in our lab testing. This behind-the-ear device ranks #17 out of 65 OTC hearing aids tested, placing it in the top 25% of its category. In our standardized testing, speech clarity in quiet environments stands out as a notable strength, scoring 3.6/5—a solid result that sits 0.85 points above the category average. Feedback handling is excellent at 5.0/5, meaning users should experience stable performance without whistling during typical wear. Own-voice comfort also performs well at 3.5/5, nearly a full point above average, which can contribute to a more natural listening experience. Speech understanding in noisy environments presents a limitation, scoring 1.5/5—essentially at the category average but low in absolute terms. This is a common challenge across OTC devices, though users seeking strong noise performance may want to compare alternatives. Music streaming scores 2.6/5, which is above the category average by 0.68 points but mixed in absolute quality. The Enhance Select 300 offers rechargeable batteries and streaming compatibility with both iPhone and Android devices, along with hands-free functionality. It has earned Expert's Choice Awards in both 2023 and 2024. Shoppers in this price range should note that alternatives like the Lucid Tala and Audicus Omni 2 score higher overall, while options like the Jabra Enhance Pro 20 at Costco offer similar sound quality at a lower price point. This device is best suited for those prioritizing speech clarity in quieter settings and stable, feedback-free performance.

The Otofonix Groove is a behind-the-ear prescription hearing aid priced at $795, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This rechargeable BTE device ranks 36th out of 36 tested prescription hearing aids, placing it in the bottom tier of its category. In our testing, the Groove demonstrated one clear strength: excellent feedback handling at 5.0/5, scoring 0.29 points above the category average. The device remained stable during our standardized challenge motions with no audible feedback issues. However, speech performance was significantly limited, with both speech in quiet and speech in noise scoring 1.0/5—falling 2.32 and 0.96 points below their respective category averages. Music streaming quality scored 0.0/5, which is 2.64 points below the prescription category average. Own-voice comfort was also low at 0.4/5 in the tuned configuration, 2.35 points below average, suggesting notable occlusion-related concerns. The normalized Initial Score of 2.7/5 and Tuned Score of 2.6/5 indicate that professional fitting adjustments did not improve overall performance. Given its positioning at the bottom of the prescription hearing aid category and the availability of lower-priced alternatives that scored higher in our testing, the Otofonix Groove may be difficult to recommend for most users seeking balanced sound quality across listening situations.